Search

Your search keyword '"Curioni-Fontecedro A"' showing total 24 results

Search Constraints

Start Over You searched for: Author "Curioni-Fontecedro A" Remove constraint Author: "Curioni-Fontecedro A" Publication Type Magazines Remove constraint Publication Type: Magazines
24 results on '"Curioni-Fontecedro A"'

Search Results

1. Lung Cancer in Switzerland

3. Clinically Significant Distress and Physical Problems Detected on a Distress Thermometer are Associated With Survival Among Lung Cancer Patients

7. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

8. Evolution and Clinical Impact of EGFRMutations in Circulating Free DNA in the BELIEF Trial

11. Activity of Afatinib in Heavily Pretreated Patients With ERBB2Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program

12. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFRmutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

13. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial

14. European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database

17. An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative

18. Résultats rapportés par les patients (PRO, patient-reported outcomes) de l’étude de phase II CodeBreaK 100 évaluant l’intérêt du sotorasib dans le traitement du cancer du poumon non à petites cellules (CPNPC) avec mutation KRAS p.G12C

19. CheckMate 817 : nivolumab + ipilimumab en première ligne chez des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) avancé avec un ECOG PS 2 et autres populations particulières

22. MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry

Catalog

Books, media, physical & digital resources